Parkinson Disease Psychosis

Neurology
3
Pipeline Programs
2
Companies
3
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
PIMAVANSERINApproved
pimavanserin
Unknown Company
oral

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Acadia Pharmaceuticals
2 programs
1
PimavanserinPhase 41 trial
Real-world, non-interventionalN/A1 trial
Active Trials
NCT03152292Terminated764Est. Mar 2021
NCT04292223Completed29Est. Apr 2022
VP
Vanda PharmaceuticalsWASHINGTON, DC
1 program
1
IloperidonePhase 21 trial
Active Trials
NCT05344365Withdrawn0Est. Nov 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Acadia PharmaceuticalsPimavanserin
Vanda PharmaceuticalsIloperidone
Acadia PharmaceuticalsReal-world, non-interventional

Clinical Trials (3)

Total enrollment: 793 patients across 3 trials

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Start: Feb 2020Est. completion: Apr 202229 patients
Phase 4Completed

A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

Start: Jun 2022Est. completion: Nov 20230
Phase 2Withdrawn
NCT03152292Acadia PharmaceuticalsReal-world, non-interventional

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Start: Mar 2017Est. completion: Mar 2021764 patients
N/ATerminated

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space